Ginkgo Bioworks Holdings Inc (DNA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. I'm joined by Jason Kelly, our co-founder and CEO, and our new CFO, Steve Cohen. Thanks as always for joining us. We're looking forward to updating you on our progress. As a reminder, during the presentation today, we'll be making forward-looking statements which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10K. Today, in addition to updating you on the quarter results, we're going to provide updates on our path towards adjusted EBITDA breakeven and dive deeper into the new deals and launches in Ginkgo's tools businesses, which continue to establish themselves as critical tools in AI-powered bioengineering. As usual, we'll end with a Q&A session and I'll take questions from journalists, investors, and the public. You can submit those questions to us in advance via X, hashtag, GinkgoResults, or email investors at ginkgobioworks.com. All right, over to you, Jason. All right. Thanks, Daniel. We always start with our mission here at Ginkgo, which is to make biology easier to engineer. Our objectives are very similar to what you've heard from me over the last few earnings calls. We're trying to reach adjusted EBITDA by the end of 2026 while maintaining a cash margin of safety, and I'm going to update on that in just a sec. We're cutting costs while serving our current customers, and then very importantly, we're expanding from an R&D solutions business into the life science tool space. And in the strategic section, you're going to hear a lot about that from me today. Before I get to that, I do want to touch on that, maintaining a cash margin of safety and the cost cutting. So you can see...